|Bid||6.00 x 800|
|Ask||11.97 x 3100|
|Day's Range||9.62 - 10.52|
|52 Week Range||9.50 - 15.90|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.67|
Stocks from eight of the 34 companies from the region that went public this year are now below their IPO price. Six others are trading at double or more where they started.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics will present at the 30th Annual Piper Jaffray Healthcare Conference.
-- STRO-001 Received Orphan Drug Designation for Treatment of Multiple Myeloma -- STRO-002 to Begin Phase 1 Trial for Patients with Ovarian and Endometrial Cancers in Early 2019 SOUTH SAN FRANCISCO, Calif. ...
- Initiation of Phase 1 Trial Planned for Early 2019 - Company's Second Cell-Free ADC Addressing Unmet Medical Need in Oncology SOUTH SAN FRANCISCO, Calif. , Nov. 13, 2018 /PRNewswire/ -- Sutro Biopharma, ...
SAN FRANCISCO, Nov. 8, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), today announced that Shalini Sharp, Chief Financial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., has been appointed to Sutro's Board of Directors. As a new member of Sutro's board, Ms. Sharp brings over 20 years of experience in the life sciences industry covering strategic financial planning, corporate and business development, risk analysis and investor relations. Ms. Sharp has been Chief Financial Officer at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on rare genetic disease treatments since 2012, where she leads the company's corporate finance, information technology, and strategy functions.
SOUTH SAN FRANCISCO, Oct. 12, 2018 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), has been granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for STRO-001 for the treatment of multiple myeloma. STRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74, a protein highly expressed in B-cell malignancies such as multiple myeloma. "There is a growing need for new treatment options for patients with multiple myeloma," commented Bill Newell, Sutro's Chief Executive Officer.
The flood of local IPOs passed last year's total of 15 in July and appears well on its way to top the recent high 34 in 2014, with four more coming this week. Here's how the stocks from this year's crop of new Bay Area public companies have performed so far.
Sutro Biopharma Inc. on Wednesday said it sold more shares than expected in its initial public offering, raising $85 million.
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...